Impact of Day 14 Peripheral Blood Chimerism after Allogeneic Hematopoietic Stem Cell Bone Transplantation on the Treatment Outcome of Non-Malignant Disease
- Author:
Young Bae CHOI
1
;
Ji Won LEE
;
Ki Woong SUNG
;
Hong Hoe KOO
;
Hee Jin KIM
;
Keon Hee YOO
Author Information
- Publication Type:Original Article
- Keywords: Chimerism; Allogeneic Hematopoietic Stem Cell Transplantation; Non-Malignant Disease
- MeSH: Bone Transplantation; Chimerism; Disease-Free Survival; Fetal Blood; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Polymerase Chain Reaction; Retrospective Studies; Stem Cells; Tissue Donors; Treatment Outcome
- From:Journal of Korean Medical Science 2019;34(6):e46-
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: The impact of early peripheral blood chimerism on the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. We aimed to determine whether day 14 peripheral blood chimerism after allo-HSCT predicts outcomes in patients with non-malignant diseases. METHODS: Data from 56 patients who received allo-HSCT between April 2007 and March 2016 were retrospectively analyzed. Chimerism was evaluated using short-tandem repeat polymerase chain reaction, with mixed chimerism (MC) defined as greater than 1% recipient cells which was further categorized into low-level MC (> 1% and < 15% of recipient-derived cells) and high-level MC (≥ 15% of the recipient-derived cells). RESULTS: Thirty-six patients showed complete donor chimerism (CC), 14 low-level MC, and 6 high-level MC at day 14 post-transplant. The estimated 5-year event-free survival (EFS) was higher in the CC or low-level MC groups than in the high-level MC group (86.1% vs. 71.4% vs. 33.3%; P = 0.001). In BM or peripheral blood stem cell (BM/PBSC) transplants, the 5-year EFS was higher in the CC or low-level MC group than in the high-level MC group (93.1% vs. 66.7% vs. 0%; P < 0.001). However, in cord blood transplants, the 5-year OS and EFS according to the day 14 peripheral blood chimerism did not reach statistical significance. CONCLUSION: Although CC is not always necessary after allo-HSCT for non-malignant diseases, our data suggest that day 14 peripheral blood chimerism may predict outcomes in patients with non-malignant diseases who underwent BM/PBSC transplants.
